Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles

Area of Science:

• Oncology
• Nanomedicine
• Biotechnology

Background:

• Glioblastomas (GB) are aggressive brain tumors with poor prognosis.
• GB cell plasticity and mesenchymal states contribute to treatment resistance.
• Targeting glioma stem cells (GSCs) is crucial for effective therapy.

Purpose of the Study:

• To develop and evaluate heparin-based nanoparticles (HP-NPs) for targeting mesenchymal-like (MES) GSCs in glioblastoma.
• To assess the efficacy and safety of HP-NPs as a precision medicine approach for glioblastoma.
• To investigate the mechanism of action of HP-NPs in reducing glioblastoma progression.

Main Methods:

• Engineering HP-NPs to cross the blood-brain barrier and target MES-like GSCs.
• Encapsulating doxorubicin (DOX) in HP-NPs to improve hemocompatibility.
• In vitro evaluation of HP-NP uptake by patient-derived GSCs.
• Preclinical assessment in patient-derived glioblastoma xenografts.
• Transcriptomic analysis to identify molecular targets and mechanisms.

Main Results:

• HP-NPs demonstrated efficient uptake by patient-derived GSCs in vitro.
• Plain HP-NPs showed superior efficacy in reducing glioblastoma progression compared to DOX-loaded HP-NPs in preclinical models.
• HP-NPs downregulated heparin-binding epidermal growth factor (HBEGF), inducing a shift from MES GSCs to less plastic astroglial-like cells.
• HP-NPs were well-tolerated and safe in healthy rats at therapeutic doses.

Conclusions:

• HP-NPs represent a promising novel therapeutic strategy for glioblastoma.
• This approach targets GSC plasticity and overcomes treatment resistance.
• HP-NPs offer a potential new paradigm to improve glioblastoma treatment outcomes and reduce recurrence.